TD Cowen Reiterates Buy Rating on GoodRx Holdings Inc. (GDRX)

TD Cowen analyst Charles Rhyee reiterated a Buy rating and $16.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX).

The analyst commented, "GDRX announced it will provide Boehringer's Humira biosimilar at a low cash price available exclusively on the GDRX platform for $550/2-pack, a 92% discount to Humira's list price. We are encouraged by the announcement, as it represents GDRX's ramped efforts to support branded mfrs. through its GDRX pricing platform, an underappreciated, meaningful growth opportunity in our view."

For an analyst ratings summary and ratings history on GoodRx Holdings Inc. click here. For more ratings news on GoodRx Holdings Inc. click here.

Shares of GoodRx Holdings Inc. closed at $8.25 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Critical One Energy closes second tranche of flow-through placement